Athersys

Athersys FCF Growth

Delisted·Oct 1, 2026

The Year-over-Year Free Cash Flow Growth of Athersys (ATHXQ) as of Nov 20, 2026 is 23.47 %. In the previous year, Year-over-Year Free Cash Flow Growth was -23.14 % — a change of -201.41% (higher).

FCF Growth

23.47 %

YoY

-201.41%

Last updated:

Year-over-Year Free Cash Flow Growth of Athersys is 2022 23.47 % . Year-over-Year Free Cash Flow Growth of Athersys was 2021 -23.14 % . It decreases by -201.41% higher compared to the previous year.

The Athersys FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2015
46.76 USD
Jan 1, 2016
9.00 USD
Jan 1, 2017
-92.33 USD
Jan 1, 2018
38.79 USD
Jan 1, 2019
-141.30 USD
Jan 1, 2020
-75.39 USD
Jan 1, 2021
-23.14 USD
Jan 1, 2022
23.47 USD
The Athersys FCF Growth history
YEARFCF GrowthYoY
23.47 %-201.41%
-23.14 %-69.30%
-75.39 %-46.65%
-141.30 %-464.26%
38.79 %-142.01%
-92.33 %-1,125.93%
9.00 %-80.75%
46.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Year-over-Year Free Cash Flow Growth of Athersys is 23.47 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Athersys since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Athersys

All Key Metrics — Athersys